Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Supplementary Financial Statement Information (Details)

v3.20.1
Supplementary Financial Statement Information (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
a. Accounts receivable and prepaid expenses      
Institutions $ 124 $ 125  
Prepaid expenses 84 105  
Other 62 104  
Total 270 334  
b. Trade payable, breakdown by currency:      
USD 35 180  
NIS 798 442  
Total 833 622  
c. Accounts payable and accruals - other:      
Employees and institutions for employees 799 385  
Provisions for vacation and others 245 196  
Other 159 38  
Total 1,203 619  
Disaggregated revenues      
Revenues from the sales of goods 1,949 739 $ 463
Revenues from the rendering of services 369 190
Revenues from licensing agreement (see Note 2(l)) 4,085
Total revenues 2,318 5,014 463
Revenues by geographical area (based on the location of customers):      
United states and Canada 2,078 4,868 223
Europe 240 146 240
Total revenues 2,318 5,014 463
Major customers      
Customer A 1,374 4,274 191
Customer B 145
Customer C 82
Customer D 419 505
Customer E 242
The changes in deferred revenues relating to goods that were not yet delivered are as follows:      
Balance at beginning of year (1,950)  
Contract liability recognized due to LB agreement (1,959)  
Revenue recognized during the period 1,008 9  
Balance at end of year [1] (942) (1,950)  
Contract liability presented in current liabilities (942) (970)  
Contract liability presented in non-current liabilities (980)  
Research and development      
Payroll and related expenses 1,954 1,968 2,136
Share-based payments 549 457 333
Subcontractors and consultants 77 296 551
Consumables and materials 304 309 194
Depreciation and amortization 354 220 227
Rent and maintenance 980 780 750
Other 224 174 299
Research and development, gross 4,442 4,204 4,490
Less:      
Participation in R&D expenses (159)
IIA participation in R&D expenses, see Note 7(a) (28) (327) (425)
Total (28) (327) (584)
Research and Development 4,414 3,877 3,906
General, administrative and marketing      
Payroll and related expenses 1,293 1,152 813
Share-based payments [2] 576 977 623
Directors' salary and insurance 415 168 114
Rent and office maintenance 84 89 89
Professional services 1,012 1,111 667
Depreciation 33 23 13
Other 243 203 147
Total 3,656 3,723 2,466
Financial expenses:      
Bank and other fees 63 17 9
Remeasurement of financial instruments 3,230 2,154 17
Other financing expenses 10 9 21
Total financial expenses $ 3,303 $ 2,180 $ 47
[1] Represents the unfulfilled performance obligation related to First BioInk.
[2] Share-based payments expenses for the year ended December 31, 2018 and 2017, include amount of $583 and $425, respectively, due to services received from Alpha, and none for the year ended December 31, 2019.